[{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Psychiatry\/Psychology","graph2":"Phase I\/ Phase II","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Apnimed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Sleep","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter","graph1":"Sleep","graph2":"Phase II","graph3":"Apnimed","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Sleep","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Apnimed \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Apnimed \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Norepinephrine transporter||Undisclosed","graph1":"Undisclosed","graph2":"Phase IV","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Moksha8 Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Licensing Agreement","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Moksha8 Pharmaceuticals"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Supernus Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Psychiatry\/Psychology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Viloxazine Hydrochloride","moa":"Undisclosed","graph1":"Psychiatry\/Psychology","graph2":"Approved FDF","graph3":"Supernus Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Psychiatry","amount2New":0,"dosageForm":"Capsule, Extended Release","sponsorNew":"Supernus Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Supernus Pharmaceuticals \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for DSSTox_CID_31511
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
